SLC5A2 and atrial fibrillation: Obese individuals' increased utilization of medications targeting the cardiovascular system, including angiotensin-converting enzyme inhibitors, diuretics, statins, beta-blockers, and more recently, GLP-1 agonists and SGLT-2 inhibitors necessitate particular consideration because of their unique characteristics and varying impacts on AF.